LEARN: Learning Environment for Artificial Intelligence in Radiotherapy New Technology

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of Sydney

About this trial

This study will develop a whole-of-body markerless tracking method for measuring the motion of the tumour and surrounding organs during radiation therapy to enable real-time image guidance.

Routinely acquired patient data will be used to improve the training, testing and accuracy of a whole-of-body markerless tracking method. When the markerless tracking method is sufficiently advanced, according to the PI of each of the data collection sites, the markerless tracking method will be run in parallel to, but not intervening with, patient treatments during data acquisition.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Will receive radiation therapy for brain, breast, head and neck, kidney, liver, pancreas, prostate, spine cancer treatment or cardiac arrhythmia treatment at a participating centre.

Will receive CT planning, and a cone beam CT scan for at least one fraction of radiation therapy.

Will receive intrafraction x-ray imaging for the liver, pancreas, prostate, spine cancer treatment or cardiac arrhythmia treatment. As intrafraction imaging is not common standard of care for brain, breast, head and neck and kidney cancer treatments there is no requirement to have intrafraction x-ray imaging data for these anatomical sites.

Provides written informed consent.

Disqualifiers

Less than 18 years of age

Trial population

300 participants, at least 30 from each of nine cohorts of anatomical sites receiving radiation therapy treatment. Eight cohorts include: those being treated for cancer at anatomical sites of brain, head and neck, breast, liver, pancreas, kidney, prostate, spine; those being treated for cardiac arrhythmia.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

300 Participants
are grouped into 9 trial groups

9

Trial groups

See each trial group below.

Group A: Brain cancer
Group B: Breast cancer
Group C: Head and neck cancer
Group D: Kidney cancer
Group E: Liver cancer
Group F: Pancreatic cancer
Group G: Prostatic cancer
Group H: Spinal neoplasm
Group I: Cardiac arrhythmia

Trial outcomes

Primary outcomes

1

Accuracy of markerless tracking

Proportion of markerless tracking within 5 mm of the ground truth for each of nine anatomical sites (cohorts)

Time frame
3 years

Secondary outcomes

1

Clinical acceptability of markerless tracking system

Proportion of radiation therapists considering the markerless tracking system acceptable using a survey

Time frame
3 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University of Sydney

Lead sponsor

Princess Alexandra Hospital, Brisbane, Australia

Collaborator

Calvary Mater Newcastle, Australia

Collaborator

Western Sydney Local Health District

Collaborator

Austin Health

Collaborator

Peter MacCallum Cancer Centre, Australia

Collaborator